News and Press - JDRF T1D Fund

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

September 13, 2021 | WATERTOWN, MA

Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker

September 07, 2021 | MONTREAL

GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation

August 11, 2021 | BOSTON, MA

Seraxis appoints Shelley Hartman, Jerry Baty and MJ Choi to the Board of Directors

August 10, 2021 | FREDERICK, MD

Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases

August 04, 2021 | SAN FRANCISCO, CA and SEATTLE, WA